Lineage Cell Therapeutics Inc Cash Flow Quality Index
Lineage Cell Therapeutics Inc cash flow quality index. Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Quality Index of -2.76x as of December 2020. Operating cash flow of $-5.64 Million is below net income of $2.04 Million, suggesting accrual-heavy earnings not yet converted to cash. See LCTX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Lineage Cell Therapeutics Inc (2016–2016)
Cash flow quality index of Lineage Cell Therapeutics Inc from 2016 to 2016. Historical Cash Flow Quality Index for Lineage Cell Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore LCTX operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Lineage Cell Therapeutics Inc Cash Flow Quality Index by Year (2016–2016)
Lineage Cell Therapeutics Inc cash flow quality index by year from 2016 to 2016. Year-by-year earnings quality comparison for Lineage Cell Therapeutics Inc. For the full cash flow conversion analysis, see how efficiently does Lineage Cell Therapeutics Inc generate cash.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -2.27x | $-42.33 Million | $18.62 Million | — |